Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

David Harding


Joined Exact Sciences: 2017

David Harding has served as our SVP, Multi-Cancer Early Detection since 2022, and previously served as Senior Vice President, Integrations, Market Access, and Strategy, Outcomes and Population Health since October 2020; and as Senior Vice President, Strategy and Business Development since 2017. Prior to joining Exact Sciences, he served as Chief Commercial Officer at T2 Biosystems, Chief Commercial Officer at OvaScience, Senior Vice President of Women's Health at Hologic, Inc., and Partner at McKinsey & Company. He holds a bachelor’s degree from the University of Southern California and a Master of Business Administration from The Wharton School at the University of Pennsylvania. Mr. Harding currently serves on the board of the Madison Symphony Orchestra and Rising Star Outreach.